Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR

1. A compound of Formula (A)

wherein

R 1 is —Z—X—Y wherein X is a linker:

each Q is independently absent or is C(O), C(O)—NR 4 , NR 4 —C(O),O—C(O)—NR 4 , NR 4 —C(O)—O, —CH 2 —, or —O—, wherein at least two carbon atoms separate the —O— from any other heteroatom group;

each T is independently absent or is alkylene, wherein one or more —CH 2 — groups of the alkylene, may each independently be replaced with a —O—, wherein the —O— are separated by at least 2 carbon atoms;

Y is an amino acid sequence, a nucleic acid sequence, or an oligomer, and

Z is absent;

each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11,12,13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, wherein if n is greater than 1, each T and each Q of each (T-Q-T-Q) is independently selected;

R 2 is —N(R 3 )—C(O)—R 3 or —N(R 3 )—C(O)—OR 3 ; and

each R 3 is independently —H, —(C 1 -C 5 )alkyl, halo-substituted (C 1 -C 5 )alkyl, or (C 3 -C 6 )cycloalkyl; and

each R 4 is independently —H, —(C 1 -C 20 )alkyl, or (C 3 -C 6 )cycloalkyl wherein one to six —CH 2 — groups of the alkyl or cycloalkyl separated by at least two carbon atoms may be replaced with —O—, —S—, or —N(R 4 )—, and —CH 3 of the alkyl may be replaced with a heteroatom group selected from —N(R 4 )2, —OR 4 , and —S(R 4 ) wherein the heteroatom groups are separated by at least 2 carbon atoms; and wherein the alkyl and cycloalkyl may be substituted with halo atoms;

or a pharmaceutically acceptable salt thereof.

2. A compound of Formula (A)

wherein

R 1 is —Z—X—Y\ or —X—Y wherein X is a linker

each Q is independently absent or is C(O), C(O)—NR 4 , NR 4 —C(O), O—C(O)—NR 4 , NR 4 —C(O)—O, —CH 2 —, or —O—, wherein at least two carbon atoms separate the —O— from any other heteroatom group;

each T is independently absent or is alkylene, wherein one or more —CH 2 — groups of the alkylene, may each independently be replaced with a —O—, wherein the —O— are separated by at least 2 carbon atoms;

Y is an amino acid sequence, a nucleic acid sequence, or an oligomer, and

Z is —C≡C—, —CH═CH—, —CH 2 —, —CH 2 —O—, —C(O)—N(R 4 )—, —CH 2 —S—, —CH 2 —S(O)—, —CH 2 —S(O) 2 —, —CH 2 —S(O) 2 —N(R 4 )—, —C(O)—O—, —CH 2 —N(R 4 )—, —CH 2 —N(R 4 )—C(O)—, —CH 2 —N(R 4 )—S(O) 2 —, —CH 2 —N(R 4 )—C(O)—O—, —CH 2 —N(R 4 )—C(O)—N(R 4 )—, —CH 2 —O—C(O)—, —CH 2 —O—C(O)—N(R 4 )—, —CH 2 —O—C(O)—O—, or aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with R 5 ;

each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11,12,13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, wherein if n is greater than 1, each T and each Q of each (T-Q-T-Q) is independently selected;

R 2 is —N(R 3 )—C(O)—R 3 or —N(R 3 )—C(O)—OR 3 ; and

each R 3 is independently —H, —(C 1 -C 5 )alkyl, halo-substituted (C 1 -C 5 )alkyl, or (C 3 -C 6 )cycloalkyl;

each R 4 is independently —H, —(C 1 -C 20 )alkyl, or (C 3 -C 6 )cycloalkyl wherein one to six —CH 2 — groups of the alkyl or cycloalkyl separated by at least two carbon atoms may be replaced with —O—, —S—, or —N(R 4 )—, and —CH 3 of the alkyl may be replaced with a heteroatom group selected from —N(R 4 ) 2 , —OR 4 , and —S(R 4 ) wherein the heteroatom groups are separated by at least 2 carbon atoms; and wherein the alkyl and cycloalkyl may be substituted with halo atoms; and

each R 5 is independently —H, (C 3 -C 20 )cycloalkyl or (C 1 -C 20 )alkyl wherein one to six —CH 2 — groups of the alkyl or cycloalkyl separated by at least two carbon atoms may be replaced with —O—, —S—, or —N(R 4 )—, and —CH 3 of the alkyl may be replaced with a heteroatom group selected from —N(R 4 ) 2 , —OR 4 , and —S(R 4 ) wherein the heteroatom groups are separated by at least 2 carbon atoms; and wherein the alkyl and cycloalkyl may be substituted with one to six halo atoms;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein R 1 is —X—Y and R 2 is —NH—C(O)—CH 3 .

4. The compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (A) is capable of binding to a receptor present on a hepatocyte.

5. The compound of claim 4 or a pharmaceutically acceptable salt thereof, wherein the receptor present on a hepatocyte is an asialoglycoprotein receptor.

6. A pharmaceutical composition comprising (i) a compound of claim 5 ; or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable excipient, diluent, or carrier.

7. The composition of claim 6 wherein said compound or said pharmaceutically acceptable salt thereof is present in a therapeutically effective amount.